RMST for Interval‐Censored Data in Oncology Clinical Trials
Statistics in Medicine · 2025
DOI: 10.1002/sim.70012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Xiyuan Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, University of Missouri-Columbia, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Neoplasms, Medical Oncology, Clinical Trials as Topic. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
In oncology studies, the assumption of proportional hazards is often questionable due to factors such as the presence of cured patients, a delayed treatment benefit, and possible treatment switching. The restricted mean survival time (RMST) has emerged as a valuable alternative summary measure to the hazard ratio (HR) in this scenario as it provides a clinically meaningful interpretation of treatment benefit without additional assumptions. As a commonly used primary endpoint, progression‐free survival (PFS) is defined as the time from randomization to the first occurrence of death or progression of disease (PD). However, PFS involves dual observation processes where, in practice, the exact death time is typically recorded, but PD is interval‐censored. This feature is also present in other commonly used primary endpoints, including event‐free survival, disease‐free survival, and relapse‐free survival. The conventional approach imputes the PD time with the right boundary of the time interval during which the PD occurs. This paper presents alternative estimation and inference approaches to estimate RMST with a mixture of right‐censored and interval‐censored data. Different approaches are explored by simulation under various plausible scenarios for oncology clinical trials with regard to the assessment frequency, randomness in the actual assessment times, and size of treatment effect. The choice of the restricted time point in RMST is also explored. The simulation results indicate that the RMST estimators that take account of the interval censoring inherent in the data are unbiased and more accurate than the conventional estimators, while the performance for two‐group comparisons is comparable. Furthermore, the performance of the proposed estimators is contingent on the scheduled assessment plan and patients' visit window.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Statistics, University of Missouri-Columbia, Columbia, Missouri, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
- School of Statistics, East China Normal University, Shanghai, China.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Institutes for Biomedical Research Co., Shanghai, China.
- Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
ORCID-Profile: Tianmeng Lyu, Lu Tian, Jianguo Sun
Zitieren
APA
Gao, X., Lyu, T., Xu, M., Hampson, L. V., Du, Y., Lin, R., Yateman, N., Tian, L., & Sun, J. (2025). RMST for Interval‐Censored Data in Oncology Clinical Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70012
Vancouver
Gao X, Lyu T, Xu M, Hampson LV, Du Y, Lin R, et al. RMST for Interval‐Censored Data in Oncology Clinical Trials. Statistics in Medicine. 2025. doi:10.1002/sim.70012
BibTeX
@article{Gao2025,
author = {Gao, Xiyuan and Lyu, Tianmeng and Xu, Menghao and Hampson, Lisa V and Du, Yan and Lin, Renxin and Yateman, Nigel and Tian, Lu and Sun, Jianguo},
title = {RMST for Interval‐Censored Data in Oncology Clinical Trials},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70012}
}
EUVIMED